-
Je něco špatně v tomto záznamu ?
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
SD. Anker, J. Butler, G. Filippatos, M. Shahzeb Khan, JP. Ferreira, E. Bocchi, M. Böhm, HP. Brunner-La Rocca, DJ. Choi, V. Chopra, E. Chuquiure, N. Giannetti, JE. Gomez-Mesa, S. Janssens, JL. Januzzi, JR. Gonzalez-Juanatey, B. Merkely, SJ....
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Grantová podpora
Boehringer Ingelheim
Eli Lilly and Company
NLK
Medline Complete (EBSCOhost)
od 2000-03-01 do Před 1 rokem
Wiley Free Content
od 1999 do Před 1 rokem
PubMed
33251670
DOI
10.1002/ejhf.2064
Knihovny.cz E-zdroje
- MeSH
- benzhydrylové sloučeniny terapeutické užití MeSH
- biologické markery krev MeSH
- diabetes mellitus 2. typu * farmakoterapie MeSH
- dvojitá slepá metoda MeSH
- glifloziny terapeutické užití MeSH
- glukosidy terapeutické užití MeSH
- kardiovaskulární látky terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- natriuretický peptid typu B krev MeSH
- peptidové fragmenty krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srdeční selhání * krev diagnóza farmakoterapie patofyziologie MeSH
- tepový objem MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
AIMS: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. METHODS AND RESULTS: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. CONCLUSION: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
ASST Papa Giovanni XXIII Bergamo Italy
Baylor University Medical Center Dallas TX USA
Boehringer Ingelheim International GmbH Ingelheim Germany
Boehringer Ingelheim Pharma GmbH and Co KG Biberach Germany
Boehringer Ingelheim Pharma Inc Ridgefield CT USA
Centre Hospitalier Régional et Universitaire de Besançon Besançon France
Centre Universitaire de Sante McGill Montreal QC Canada
Charité Universitätsmedizin Berlin Berlin Germany
Complejo Hospitalario Universitario de Santiago CIBERCV A Coruña Spain
Department of Cardiology Berlin Germany
Department of Cardiology FLENI Institute Buenos Aires Argentina
Department of Clinical and Experimental Medicine University of Pisa Pisa Italy
Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK
Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany
Fundación Valle del Lili Cali Colombia
Fuwai Hospital Chinese Academic of Medical Science Beijing China
German Centre for Cardiovascular Research Partner Site Berlin Berlin Germany
Harvard Medical School Massachusetts General Hospital Boston MA USA
Instituto Nacional de Cardiologia Ignacio Chavez Ciudad de Mexico Mexico
Kyushu University Fukuoka City Japan
Maastricht University Medical Center Maastricht The Netherlands
Medanta Medicity to Max Superspeciality Hospital Saket New Delhi India
National and Kapodistrian University of Athens School of Medicine Athens Greece
National Heart Centre Singapore
NIHR Cardiovascular Biomedical Research Centre Glenfield Hospital Leicester UK
São Paulo University Medical School São Paulo Brazil
Semmelweis University Budapest Hungary
Seoul National University Bundang Hospital Seoul Republic of Korea
St Michael's Hospital University of Toronto Toronto ON Canada
Université de Lorraine Inserm INI CRCT Nancy France
University Hospital Masaryk University Hospital Brno Czech Republic
University Hospitals Leuven Belgium Brazil
University of Medicine and Pharmacy Carol Davila University and Emergency Hospital Bucharest Romania
University of Mississippi School of Medicine Jackson MI USA
Victorian Heart Institute Monash University Clayton VIC Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019713
- 003
- CZ-PrNML
- 005
- 20210830101309.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ejhf.2064 $2 doi
- 035 __
- $a (PubMed)33251670
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Anker, Stefan D $u Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany $u German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Berlin, Germany $u Charité Universitätsmedizin Berlin, Berlin, Germany
- 245 10
- $a Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial / $c SD. Anker, J. Butler, G. Filippatos, M. Shahzeb Khan, JP. Ferreira, E. Bocchi, M. Böhm, HP. Brunner-La Rocca, DJ. Choi, V. Chopra, E. Chuquiure, N. Giannetti, JE. Gomez-Mesa, S. Janssens, JL. Januzzi, JR. Gonzalez-Juanatey, B. Merkely, SJ. Nicholls, SV. Perrone, IL. Piña, P. Ponikowski, M. Senni, MF. Seronde, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, W. Jamal, S. Schnaidt, JM. Schnee, M. Brueckmann, SJ. Pocock, F. Zannad, M. Packer, EMPEROR-Preserved Trial Committees and Investigators
- 520 9_
- $a AIMS: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. METHODS AND RESULTS: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. CONCLUSION: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a benzhydrylové sloučeniny $x terapeutické užití $7 D001559
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a kardiovaskulární látky $x terapeutické užití $7 D002317
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glukosidy $x terapeutické užití $7 D005960
- 650 12
- $a srdeční selhání $x krev $x diagnóza $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a natriuretický peptid typu B $x krev $7 D020097
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a glifloziny $x terapeutické užití $7 D000077203
- 650 _2
- $a tepový objem $7 D013318
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Butler, Javed $u University of Mississippi School of Medicine, Jackson, MI, USA
- 700 1_
- $a Filippatos, Gerasimos $u National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- 700 1_
- $a Shahzeb Khan, Muhammad $u University of Mississippi School of Medicine, Jackson, MI, USA
- 700 1_
- $a Ferreira, João Pedro $u Université de Lorraine, Inserm INI-CRCT, Nancy, France
- 700 1_
- $a Bocchi, Edimar $u São Paulo University Medical School, São Paulo, Brazil
- 700 1_
- $a Böhm, Michael $u Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homberg, Germany
- 700 1_
- $a Brunner-La Rocca, Hans Pieter $u Maastricht University Medical Center, Maastricht, The Netherlands
- 700 1_
- $a Choi, Dong-Ju $u Seoul National University Bundang Hospital, Seoul, Republic of Korea
- 700 1_
- $a Chopra, Vijay $u Medanta Medicity to Max Superspeciality Hospital, Saket, New Delhi, India
- 700 1_
- $a Chuquiure, Eduardo $u Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico
- 700 1_
- $a Giannetti, Nadia $u Centre Universitaire de Sante McGill, Montreal, QC, Canada
- 700 1_
- $a Gomez-Mesa, Juan Esteban $u Fundación Valle del Lili, Cali, Colombia
- 700 1_
- $a Janssens, Stefan $u University Hospitals Leuven, Belgium, Brazil
- 700 1_
- $a Januzzi, James L $u Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
- 700 1_
- $a Gonzalez-Juanatey, Jose R $u Complejo Hospitalario Universitario de Santiago, CIBERCV, A Coruña, Spain
- 700 1_
- $a Merkely, Bela $u Semmelweis University, Budapest, Hungary
- 700 1_
- $a Nicholls, Stephen J $u Victorian Heart Institute, Monash University, Clayton, VIC, Australia
- 700 1_
- $a Perrone, Sergio V $u Department of Cardiology, FLENI Institute, Buenos Aires, Argentina
- 700 1_
- $a Piña, Ileana L $u Wayne State University, Detroit, MI, USA
- 700 1_
- $a Ponikowski, Piotr $u Wrocław Medical University, Wroclaw, Poland
- 700 1_
- $a Senni, Michele $u ASST Papa Giovanni XXIII, Bergamo, Italy
- 700 1_
- $a Seronde, Marie-France $u Centre Hospitalier Régional et Universitaire de Besançon, Besançon, France
- 700 1_
- $a Sim, David $u National Heart Centre, Singapore
- 700 1_
- $a Spinar, Jindrich $u University Hospital, Masaryk University Hospital, Brno, Czech Republic
- 700 1_
- $a Squire, Iain $u NIHR Cardiovascular Biomedical Research Centre, Glenfield Hospital, Leicester, UK
- 700 1_
- $a Taddei, Stefano $u Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 700 1_
- $a Tsutsui, Hiroyuki $u Kyushu University, Fukuoka City, Japan
- 700 1_
- $a Verma, Subodh $u St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania
- 700 1_
- $a Zhang, Jian $u Fuwai Hospital Chinese Academic of Medical Science, Beijing, China
- 700 1_
- $a Jamal, Waheed $u Boehringer Ingelheim International GmbH, Ingelheim, Germany
- 700 1_
- $a Schnaidt, Sven $u Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- 700 1_
- $a Schnee, Janet M $u Boehringer Ingelheim Pharma, Inc., Ridgefield, CT, USA
- 700 1_
- $a Brueckmann, Martina $u Boehringer Ingelheim International GmbH, Ingelheim, Germany $u Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany
- 700 1_
- $a Pocock, Stuart J $u Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
- 700 1_
- $a Zannad, Faiez $u Université de Lorraine, Inserm INI-CRCT, Nancy, France
- 700 1_
- $a Packer, Milton $u Baylor University Medical Center, Dallas, TX, USA $u Imperial College, London, UK
- 710 2_
- $a EMPEROR-Preserved Trial Committees and Investigators
- 773 0_
- $w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 22, č. 12 (2020), s. 2383-2392
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33251670 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101308 $b ABA008
- 999 __
- $a ok $b bmc $g 1690511 $s 1140159
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 22 $c 12 $d 2383-2392 $e - $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
- GRA __
- $p Boehringer Ingelheim
- GRA __
- $p Eli Lilly and Company
- LZP __
- $a Pubmed-20210728
